For the year ending 2025-12-31, NVAX had -$289,240K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 440,302 |
| Depreciation and amortization | 27,613 |
| Gain on disposition of novavax cz assets | 0 |
| Right-of-use assets expensed, net of credits received | 0 |
| Stock-based compensation | 36,015 |
| Provision for excess and obsolete inventory | 1,945 |
| Impairment of assets held for sale | 97,845 |
| Impairment of other long-lived assets | 4,880 |
| Loss on debt extinguishment | -28,714 |
| Other items, net | -5,756 |
| Inventory | 3,240 |
| Accounts receivable, prepaid expenses, and other assets | -61,040 |
| Accounts payable, accrued expenses, and other liabilities | -322,566 |
| Deferred revenue | -622,939 |
| Net cash used in operating activities | -244,635 |
| Capital expenditures | 5,560 |
| Internal-use software | 828 |
| Proceeds from assets held for sale | 19,653 |
| Proceeds from disposition of novavax cz assets | 0 |
| Purchases of marketable securities | 445,267 |
| Proceeds from maturities of marketable securities | 353,735 |
| Net cash used in investing activities | -78,267 |
| Net proceeds from sales of common stock | 0 |
| Proceeds on the issuance of convertible senior notes due 2031, net of issuance costs | 42,606 |
| Payments of costs related to issuance of 2027 convertible notes | 0 |
| Proceeds from the exercise of stock-based awards, net of tax withholding | -4,798 |
| Repayment of 2023 convertible notes | 0 |
| Finance lease payments | 10,071 |
| Net cash provided by financing activities | 27,737 |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | 5,925 |
| Net decrease in cash, cash equivalents, and restricted cash | -289,240 |
| Cash, cash equivalents, and restricted cash at beginning of year | 545,292 |
| Cash, cash equivalents, and restricted cash at end of year | 256,052 |
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)